MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Press releases

Stay current with the latest press releases from within the industry.

New Research Formula for Diabetics with Cardiovascular Complications

Release issued 17th September 2009

"High blood glucose levels are one of the most common killers of Americans, according to new research from Harvard researchers." (Nutraingredients.com) "About 60% of people with type II diabetes die of atherosclerotic cardiovascular disease." (National Diabetes Advisory Board, 1987) Most of them are premature deaths when the people concerned are economically contributing to society. This situation is increasingly outstretching the health-care resources devoted to diabetes. (WHO, Fact Sheet N° 236, Revised September 2002). "Increased nitrotyrosine has been found in the plasma of diabetic patients and has been shown to be involved in the pathogenesis of atherosclerosis" (Ceriello A et al).
Exotic Naturals, CEO, Jayesh Chaudhary stated, "As the number of people with diabetes grows up to 230 millions worldwide, treatment of its long term complications take an ever-increasing proportion of national health care budgets. As per Exotic Naturals' vision to improve human life, the utmost need is created for a natural product which can support diabetics with cardiovascular complications."
Exotic Naturals' focus was to develop the herbal supplement with clinically proven efficacy & safety. Hence, this research-based firm took up development of E-DM-13, an effective solution to this worldwide phenomenon. In a clinical study of 126 patients with type 2 diabetes investigators were amazed to find that E-DM-13 could dramatically decrease (p<0.001) serum nitrotyrosine levels by a huge 90% compared to before treatment. E-DM-13 produced significant (p<0.05) improvements in levels of glycosylated hemoglobin (HbA1c), a standard indicator for glycemic control. Also fasting and post prandial plasma glucose levels showed a significant decrease compared to baseline (p<0.05). Unlike the inadequate safety profile of conventional drugs, E-DM-13 was found to be free from major side effects. No severe adverse events were noted during the study period. E-DM-13 also clears mutagenecity and genotoxicity tests and has undergone animal research over the last 4 years of development.
Company profile
Exotic Naturals is an innovation driven company which is focused on design and development of dietary ingredients and formulas with substantiated label claims. In keeping with its mission, Exotic has developed products in some of the fastest growing health categories - Male Sexual Dysfunction, Lipid Lowering and Diabetes Type 2, Allergies, Insomnia, Osteoarthritis & Antioxidants and lots more at the R&D stage. Exotic Naturals is offering these opportunities to alliance partners for co-development and co-marketing worldwide.
For more information on Exotic Naturals & its products visit www.exoticnatural.com or contact Rekha Patel (bizdev@exoticnatural.com)
 
 
 

Company details

If you want to find out more about the company visit Exotic Naturals profile.

Latest Exotic Naturals press releases

More Press Releases

Related categories

Therapeutic target
Cardiovascular
Metabolism
Oral Health
Industry sector
Academic/Research
Biotechnology
Drug discovery
Service

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us